BIOMAT Database Logo BIOMAT Database Logo

Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour. 2000

M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Department of Endocrinology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.

OBJECTIVE The aim of this study was to prove the utility of GnRH analogues for the suppression of androgen secretion in a postmenopausal woman with a suspected virilizing ovarian tumour. METHODS We present a case of a 72-year-old woman with virilization of recent onset. Hormonal studies revealed a fourfold increase in serum testosterone levels, normal dehydroepiandrosterone sulphate concentrations and high levels of serum 17-hydroxyprogesterone levels. Computed axial tomography scan of the ovaries was normal and the adrenal glands showed a discrete enlargement. The long-acting GnRH analogue, triptorelin, was injected initially (3.75mg i.m.) and serum hormone levels were measured weekly throughout one month. RESULTS GnRH produced a decrease in serum testosterone levels to normal values, in parallel with the suppression of serum LH and FSH concentrations. The patient was treated for three months with triptorelin and she experienced an amelioration of the hyperandrogenic symptoms. In order to achieve a diagnosis, the patient was submitted to a laparotomy that revealed a small hilus cell tumour in the left ovary. CONCLUSIONS GnRH analogues may offer a good therapeutic option in some states of gonadotrophin-dependent hyperandrogenism of ovarian origin.

UI MeSH Term Description Entries
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006628 Hirsutism A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D017329 Triptorelin Pamoate A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6. D-Trp-6-LH-RH,LHRH, Trp(6)-,Triptorelin,6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig),AY-25650,CL-118532,Decapeptyl,Decapeptyl Depot,Decapeptyl LP,Decapeptyl Trimestral,GnRH, Trp(6)-,LHRH, Tryptophyl(6)-,Trelstar,Triptorelin Embonate,Wy-42462,AY 25650,AY25650,CL 118532,CL118532,Embonate, Triptorelin,Pamoate, Triptorelin,Trimestral, Decapeptyl,Wy 42462,Wy42462
D017588 Hyperandrogenism A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
D017698 Postmenopause The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life. Post-Menopause,Post-menopausal Period,Postmenopausal Period,Period, Post-menopausal,Period, Postmenopausal,Post Menopause,Post menopausal Period,Post-Menopauses

Related Publications

M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women.
January 2018, Endocrinology, diabetes & metabolism case reports,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
A rare case of postmenopausal hyperandrogenism due to ovarian hyperthecosis and hilus cell hyperplasia.
March 2022, Post reproductive health,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
GnRH analogue use in postmenopausal hyperandrogenism: long-term remission.
April 2012, Endocrine,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Gonadotropin-Releasing Hormone Analogue Stimulation Test Versus Venous Sampling in Postmenopausal Hyperandrogenism.
January 2021, Journal of the Endocrine Society,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Repetitive treatment with gonadotrophin releasing factor or a long-acting analogue upon gonadotrophin secretion in the ferret.
August 1981, The Journal of endocrinology,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Pulsatile subcutaneous versus bolus intramuscular gonadotrophin administration after pituitary suppression with a long-acting gonadotrophin-releasing hormone analogue: a controlled prospective study.
June 1994, Human reproduction (Oxford, England),
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Gonadotrophin-release upon iv-administration of a long-acting analogue of luteinizing hormone-releasing hormone in male patients with elevated serum estradiol-concentrations due to chronic liver disease.
December 1980, Endokrinologie,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle.
November 1997, Human reproduction (Oxford, England),
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
Gonadotrophin hormone-releasing hormone analogue treatment of fibroids.
June 1998, Bailliere's clinical obstetrics and gynaecology,
M J Picón, and J I Lara, and J L Sarasa, and J D Recasens, and R Clouet, and M A Gonzalo, and A Rovira
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
January 1988, American journal of clinical oncology,
Copied contents to your clipboard!